Access the full text.
Sign up today, get DeepDyve free for 14 days.
Paul Hartig, Daniel Hoyer, Patrick Humphrey, Graeme Martin (1996)
Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes.Trends in pharmacological sciences, 17 3
H. Rollema, T. Clarke, J. Sprouse, D. Schulz (1996)
Combined Administration of a 5‐Hydroxytryptamine (5‐HT)1D Antagonist and a 5‐HT Reuptake Inhibitor Synergistically Increases 5‐HT Release in Guinea Pig Hypothalamus In VivoJournal of Neurochemistry, 67
Price Price, Burton Burton, Roberts Roberts, Watson Watson, Duckworth Duckworth, Gaster Gaster, Middlemiss Middlemiss, Jones Jones (1996)
SB 216641 and BRL 15572 pharmacologically discriminate between h5‐HT 1B and h5‐HT 1D receptorsBr. J. Pharmacol., 119
R. Invernizzi, S. Belli, R. Samanin (1992)
Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortexBrain Research, 584
C. Davidson, J. Stamford (1995)
Evidence that 5‐hydroxytryptamine release in rat dorsal raphé nucleus is controlled by 5‐HT1A, 5‐HT1B and 5‐HT1D autoreceptorsBritish Journal of Pharmacology, 114
D. Middlemiss, P. Hutson (1990)
The 5‐HT1B ReceptorsAnnals of the New York Academy of Sciences, 600
M. Åsberg, B. Eriksson, B. Mårtensson, L. Träskman-bendz, A. Wägner (1986)
Therapeutic effects of serotonin uptake inhibitors in depression.The Journal of clinical psychiatry, 47 Suppl
Arborelius (1995)
5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopramNaunyn-Schmiedeberg's Arch. Pharmacol., 352
M. Hajós, S. Gartside, A. Villa, T. Sharp (1995)
Evidence for a repetitive (burst) firing pattern in a sub-population of 5-hydroxytryptamine neurons in the dorsal and median raphe nuclei of the ratNeuroscience, 69
A. Schatzberg, D. Ec, P. O'Neil, D. Katz, J. Cole (1987)
Recent Studies on Selective Serotonergic AntidepressantsJournal of Clinical Psychopharmacology, 7
C. Gundlah, S. Hjorth, S. Auerbach (1997)
Autoreceptor Antagonists Enhance the Effect of the Reuptake Inhibitor Citalopram on Extracellular 5-HT: this Effect Persists After Repeated Citalopram TreatmentNeuropharmacology, 36
R. Invernizzi, M. Bramante, R. Samanin (1996)
Role of 5-HT1A receptors in the effects of acute and chronic fluoxetine on extracellular serotonin in the frontal cortexPharmacology Biochemistry and Behavior, 54
G. Price, M. Burton, L. Collin, M. Duckworth, L. Gaster, M. Göthert, B. Jones, C. Roberts, J. Watson, D. Middlemiss (1997)
SB-216641 and BRL-15572 – compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptorsNaunyn-Schmiedeberg's Archives of Pharmacology, 356
S. Gartside, V. Umbers, M. Hajós, T. Sharp (1995)
Interaction between a selective 5‐HT1A receptor antagonist and an SSRI in vivo: effects on 5‐HT cell firing and extracellular 5‐HTBritish Journal of Pharmacology, 115
S. Starkey, M. Skingle (1994)
5-HT1D as well as 5-HT1A autoreceptors modulate 5-HT release in the guinea-pig dorsal raphénucleusNeuropharmacology, 33
S. Hjorth (1993)
Serotonin 5‐HT1A Autoreceptor Blockade Potentiates the Ability of the 5‐HT Reuptake Inhibitor Citalopram to Increase Nerve Terminal Output of 5‐HT In Vivo: A Microdialysis StudyJournal of Neurochemistry, 60
P. Pauwels, F. Colpaert (1995)
The 5-HT1Dreceptor antagonist GR 127,935 is an agonist at cloned human 5-HT1Dα receptor sitesNeuropharmacology, 34
(1993)
Autoradio - graphic characterisation and localisation of 5 - HT 1 D compared to 5 - HT 1 B binding sites in rat brain
Skingle Skingle, Beattie Beattie, Scopes Scopes, Starkey Starkey, Connor Connor, Feniuk Feniuk, Tyers Tyers (1996)
GR127935: a potent and selective 5‐HT 1D receptor antagonistBehav. Brain Res., 73
A. Fletcher, E. Forster, D. Bill, Geraldine Brown, I. Cliffe, J. Hartley, Deborah Jones, A. McLenachan, K. Stanhope, D. Critchley, K. Childs, V. Middlefell, L. Lanfumey, R. Corradetti, A. Laporte, H. Gozlan, M. Hamon, C. Dourish (1995)
Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonistBehavioural Brain Research, 73
R. Invernizzi, C. Velasco, M. Bramante, A. Longo, R. Samanin (1997)
Effect of 5-HT1A Receptor Antagonists on Citalopram-induced Increase in Extracellular Serotonin in the Frontal Cortex, Striatum and Dorsal HippocampusNeuropharmacology, 36
A. Schatzberg, E. Dessain, P. O'Neil, D. Katz, J. Cole (1987)
Recent Studies on Selective Serotonergic Antidepressants: Trazodone, Fluoxetine, and FluvoxamineJournal of Clinical Psychopharmacology, 7
P. Blier, R. Bergeron (1995)
Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression.Journal of clinical psychopharmacology, 15 3
Chaput (1986)
Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brainNaunyn-Schmeideberg's Arch. Pharmacol., 333
S. Auerbach, J. Lundberg, S. Hjorth (1995)
Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administrationNeuropharmacology, 34
(1996)
Antidepressant action on anatomically distinct 5 - HT pathways : combined electrophysiological and neurochemical studies
F. Artigas, V. Pérez, E. Álvarez (1994)
Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors.Archives of general psychiatry, 51 3
M. Skingle, D. Beattie, Dic Scopes, S. Starkey, H. Connor, W. Feniuk, M. Tyers (1995)
GR127935: a potent and selective 5-HT1D receptor antagonistBehavioural Brain Research, 73
P. Pauwels, C. Palmier (1995)
Functional effects of the 5-HT1D receptor antagonist GR 127,935 at human 5-HT1Dα, 5-HT1Dβ, 5-HT1A and opposum 5-HT1B receptorsEuropean Journal of Pharmacology, 290
Hajós (1995a)
Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetineNaunyn-Schmeideberg's Arch. Pharmacol., 351
M. Skingle, A. Sleight, W. Feniuk (1995)
Effects of the 5-HT1D receptor antagonist GR127935 on extracellular levels of 5-HT in the guinea-pig frontal cortex as measured by microdialysisNeuropharmacology, 34
F. Artigas, L. Romero, C. Montigny, P. Blier (1996)
Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonistsTrends in Neurosciences, 19
Selective 5‐hydroxytryptamine (5‐HT; serotonin) reuptake inhibitors (SSRIs) cause a greater increase in extracellular 5‐HT in the forebrain when the somatodendritic 5‐HT1A autoreceptor is blocked. Here, we investigated whether blockade of the terminal 5‐HT1B autoreceptor influences a selective 5‐HT reuptake inhibitor in the same way, and whether there is an additional effect of blocking both the 5‐HT1A and 5‐HT1B autoreceptors. Extracellular 5‐HT was measured in frontal cortex of the anaesthetized rat by use of brain microdialysis. In vivo extracellular recordings of 5‐HT neuronal activity in the dorsal raphe nucleus (DRN) were also carried out. The selective 5‐HT reuptake inhibitor, paroxetine (0.8 mg kg−1, i.v.), increased extracellular 5‐HT about 2 fold in rats pretreated with the 5‐HT1A receptor antagonist, WAY100635. When administered alone neither paroxetine (0.8 mg kg−1, i.v.) nor WAY100635 (0.1 mg kg−1, i.v.) altered extracellular 5‐HT levels. Paroxetine (0.8 mg kg−1, i.v.) did not increase 5‐HT in rats pretreated with the 5‐HT1B/D receptor antagonist, GR127935 (1 mg kg−1, i.v.). GR127935 (1 and 5 mg kg−1, i.v.) had no effect on extracellular 5‐HT when administered alone. Interestingly, paroxetine (0.8 mg kg−1, i.v.) caused the greatest increase in 5‐HT (up to 5 fold) when GR127935 (1 or 5 mg kg−1, i.v.) was administered in combination with WAY100635 (0.1 mg kg−1, i.v.). Administration of GR127935 (5 mg kg−1, i.v.) plus WAY100635 (0.1 mg kg−1, i.v.) without paroxetine, had no effect on extracellular 5‐HT in the frontal cortex. Despite the lack of effect of GR127935 on 5‐HT under basal conditions, when 5‐HT output was elevated about 3 fold (by adding 1 μM paroxetine to the perfusion medium), the drug caused a dose‐related (1 and 5 mg kg−1, i.v.) increase in 5‐HT. By itself, GR127935 slightly but significantly decreased 5‐HT cell firing in the DRN at higher doses (2.0–5.0 mg kg−1, i.v.), but did not prevent the inhibition of 5‐HT cell firing induced by paroxetine. In summary, our results suggest that selective 5‐HT reuptake inhibitors may cause a large increase in 5‐HT in the frontal cortex when 5‐HT autoreceptors on both the somatodendrites (5‐HT1A) and nerve terminals (5‐HT1B) are blocked. This increase is greater than when either set of autoreceptors are blocked separately. The failure of a 5‐HT1B receptor antagonist alone to enhance the effect of the selective 5‐HT reuptake inhibitor in our experiments may be related to a lack of tone on the terminal 5‐HT1B autoreceptor due to a continued inhibition of 5‐HT cell firing. These results are discussed in relation to the use of 5‐HT autoreceptor antagonists to augment the antidepressant effect of selective 5‐HT reuptake inhibitors.
British Journal of Pharmacology – Wiley
Published: Jul 1, 1997
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.